title: Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A.
abstract: OBJECTIVE
  To evaluate the levels of serum chemokines in patients with psoriatic arthritis (PsA) before and during cyclosporin A (CyA) treatment.
  
  
  METHODS
  Sixteen outpatients with active PsA were followed for 6 months during low dosage CyA treatment. Serum chemokines of the C-X-C and C-C groups were determined by ELISA at the baseline. Serum RANTES levels were measured at 2 month intervals for 6 months. Serum chemokine levels were related with clinical and laboratory disease activity variables.
  
  
  RESULTS
  Serum interleukin 8 and macrophage inflammatory protein 1alpha levels were undetectable at baseline. Mean serum growth related gene product-alpha and monocyte chemoattractant protein 1 values were reduced and serum RANTES were elevated compared to controls. CyA treatment did not change serum RANTES levels. Patients with PsA with persistently normal serum RANTES levels (4 patients) had a more favorable clinical and laboratory response to CyA compared to patients with persistently high serum levels (6 patients).
  
  
  CONCLUSIONS
  Serum RANTES levels are higher in patients with PsA than in a control population. CyA treatment does not change RANTES values. Patients with PsA with persistently normal RANTES levels have a better response to CyA treatment.
authors.affiliation: Unita' Reumatologica, Azienda Ospedaliera Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Macchioni
authors.forename: L
authors.initials: L
authors.lastname: Boiardi
authors.forename: R
authors.initials: R
authors.lastname: Meliconi
authors.forename: L
authors.initials: L
authors.lastname: Pulsatelli
authors.forename: M C
authors.initials: MC
authors.lastname: Maldini
authors.forename: R
authors.initials: R
authors.lastname: Ruggeri
authors.forename: A
authors.initials: A
authors.lastname: Facchini
authors.forename: C
authors.initials: C
authors.lastname: Salvarani
mesh_terms: D000328:Adult; D000368:Aged; D015535:Arthritis, Psoriatic / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy; D018932:Chemokine CCL2 / Q000097:blood; D054407:Chemokine CCL4; D018946:Chemokine CCL5 / Q000097:blood; D018925:Chemokines / Q000097:blood*; D016572:Cyclosporine / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016209:Interleukin-8 / Q000097:blood; D019402:Macrophage Inflammatory Proteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D013997:Time Factors
chemical_list: D018932:Chemokine CCL2; D054407:Chemokine CCL4; D018946:Chemokine CCL5; D018925:Chemokines; D016209:Interleukin-8; D019402:Macrophage Inflammatory Proteins; D016572:Cyclosporine